

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**Complete if Known**

Application Number	10/584829
Filing Date	June 26, 2005
First Named Inventor	ASAKI, Tetsuo
Art Unit	1621
Examiner Name	S. Kumar
Attorney Docket Number	44342 025000

(Use as many sheets as necessary)

Sheet 1 of 2

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>2</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
		Country Code <sup>3</sup> *Number* *Kind Code <sup>4</sup> (# known)				
/SK/		WO 02/22597 A1	03-21-2002	Buerger, et. al.		
/SK/		EP O 564 409 A1	03-25-1993	Ciba-Geigy AG		
/SK/		WO 2004/014903 A1	02-19-2004	M. Ciufolini, et. al.		

Examiner Signature: /Shailendra Kumar/

Date Considered	05/08/2009
-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

**Translations and/or:** Translation is required by 37 CFR 1.97 and 1.99. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

American LegalNet, Inc.  
www.USCourtForms.com

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

## Complete if Known

Application Number	TBA <b>10/584829</b>
Filing Date	June 26, 2005
First Named Inventor	ASAKI, Tetsuo
Art Unit	<del>TBA</del> 1621
Examiner Name	<del>TBA</del> S. Kumar
Attorney Docket Number	44342.025000

Sheet **2**

of **2**

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/SK/		S. KIMURA, et. al., NS-187, a Potent and Selective Dual Bcr-Abl/Lyn Tyrosine Kinase Inhibitor, is a Novel Agent for Imatinib-Resistant Leukemia, Blood, Vol. 16, No. 12, 3948-3954 (December 1, 2005)	
/SK/		T. ASAKI, et. al., Design and Synthesis of 3-substituted Benzamide Derivatives as Bcr-Abl Kinase Inhibitors, 16 Bioorganic & Medicinal Chemistry Letters 1421-1425 (2006)	
/SK/		R. PARISE, et. al., Liquid Chromatographic - Mass Spectrometric Assay for Quantitation of Imatinib and its Main Metabolite (CGP 74588) in Plasma, 791 J. Chromatography B 39-44 (2003)	
/SK/		B. DRUKER, et. al., Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crises of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome, N. Engl. J. Med., Vol. 344, No. 14, 1038-1042 (April 5, 2001)	
/SK/		M. GORRE, et. al., Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation and Amplification, Science, Vol. 293 876-880 (August 3, 2001)	
/SK/		MV BLAGOSKLONNY, STI-571 Must Select for Drug-Resistant Cells but 'No Cell Breathes Fire Out of its Nostrils Like a Dragon', 16 Leukemia 570-572 (2002)	
/SK/		A. HOCHHAUS, et. al., Molecular and Chromosomal Mechanisms of Resistance to Imatinib (STI 1571) Therapy, 16 Leukemia 2190-2196 (2002)	
/SK/		W.K. HOFMANN, et. al., Ph+ Acute Lymphoblastic Leukemia Resistant to the Tyrosine Kinase Inhibitor STI 1571 has a Unique BCR-ABL Gene Mutation, Blood, Vol. 99, No. 5 1860-1862 (March 1, 2002)	
/SK/		M. DEININGER, et. al., The Molecular Biology of Chronic Myeloid Leukemia, Blood, Vol. 96, No. 10 3343-3356 (November 15, 2000)	

Examiner  
Signature

/Shailendra Kumar/

Date  
Considered

05/08/2009

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.